Novo Nordisk's next-gen obesity drug Cagrisema
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online search trends, according to a study published online Jan. 29 in JAMA Network ...
Comprehensive study exposes critical health risks of obesity, including diabetes, heart disease, and cancer, while offering ...
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...
Experts from AIIMS Delhi emphasised obesity’s harmful health effects and the need for preventive actions, supporting Prime ...
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback